Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Summary by The Manila Times
Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support the start of a Phase 1b clinical...

4 Articles

The Manila TimesThe Manila Times
+2 Reposted by 2 other sources
Lean Right

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support the start of a Phase 1b clinical...

·Manila, Philippines (the)
Read Full Article
pharmatimes.compharmatimes.com

JJP Biologics reports positive interim phase 1b data for nebaprubart

Early clinical activity supports expansion into broader IgA‑mediated conditions

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Manila Times broke the news in Manila, Philippines (the) on Wednesday, June 3, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Manila icon

Manila

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal